publication date: Sep. 4, 2020
NCI Trials
NCI Trials for September 2020
The National Cancer Institute approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I/II – 10382
A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer
Yale University Cancer Center LAO
Bagegni, Nusayba
(314) 747-1171
Phase II – ANBL19P1
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
Children’s Oncology Group
Desai, Ami V.
773-834-3943
Phase II – EA6191
The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma
ECOG-ACRIN Cancer Research Group
Amaravadi, Ravi
(215) 796-5159
Phase II/III – NRG-LU007
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
NRG Oncology
Nguyen, Quynh-Nhu
(713) 563-2447
Phase III – A011801
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Alliance for Clinical Trials in Oncology
O’Sullivan, Ciara C.
(507) 293-0526
Phase III – NRG-GU009
Parallel Phase III Randomized Trials for High Risk Prostate … Continue reading NCI Trials for September 2020To access this members-only content, please log in.Institutional subscribers, please
log in with your IP.
If you're not a subscriber why not
join today? To gain access to the members only content
click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
